A novel role of EMMPRIN/CD147 in transformation of quiescent fibroblasts to cancer-associated fibroblasts by breast cancer cells

Cancer Letters

Volumn 335, Issue 2, 2013, Pages 380-386

  Xu, Jing ^a,b   Lu, Yang ^a   Qiu, Songbo ^a   Chen, Zhi Nan ^b   Fan, Zhen ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Unit 1950   (United States)

Author keywords

SMA; Cancer stroma; Cancer associated fibroblasts; EMMPRIN CD147; Epithelial to mesenchymal transition

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD147 ANTIGEN;

ARTICLE; CANCER CELL; CELL MIGRATION; CELL STRAIN MCF 7; CELL TRANSFORMATION; COCULTURE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ACTINS; ANTIGENS, CD147; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBROBLASTS; HUMANS;

EID: 84878217375     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.054     Document Type: Article

References (48)

1. Littlepage L.E., Egeblad M., Werb Z. Coevolution of cancer and stromal cellular responses. Cancer Cell 2005, 7:499-500.
2. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., Kaminker J., Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15:21-34.
5. Orimo A., Gupta P.B., Sgroi D.C., Renzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
6. Hawsawi N.M., Ghebeh H., Hendrayani S.F., Tulbah A., Al-Eid M., Al-Tweigeri T., Ajarim D., Alaiya A., Dermime S., Aboussekhra A. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res. 2008, 68:2717-2725.
7. Hinz B., Celetta G., Tomasek J.J., Gabbiani G., Chaponnier C. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell 2001, 12:2730-2741.
8. Loeffler M., Kruger J.A., Niethammer A.G., Reisfeld R.A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 2006, 116:1955-1962.
9. Micke P., Ostman A. Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert. Opin. Ther. Targets 2005, 9:1217-1233.
10. Lebret S.C., Newgreen D.F., Thompson E.W., Ackland M.L. Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res. 2007, 9:R19.
11. Soon P.S., Kim E., Pon C.K., Gill A.J., Moore K., Spillane A.J., Benn D.E., Baxter R.C. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocr. Relat Cancer 2013, 20:1-12.
12. Ronnov-Jessen L., Petersen O.W. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest. 1993, 68:696-707.
13. Micke P., Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer 2004, 45(Suppl. 2):S163-S175.
14. Riethdorf S., Reimers N., Assmann V., Kornfeld J.W., Terracciano L., Sauter G., Pantel K. High incidence of EMMPRIN expression in human tumors. Int. J. Cancer 2006, 119:1800-1810.
15. Biswas C., Zhang Y., DeCastro R., Guo H., Nakamura T., Kataoka H., Nabeshima K. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995, 55:434-439.
16. Yu X.L., Hu T., Du J.M., Ding J.P., Yang X.M., Zhang J., Yang B., Shen X., Zhang Z., Zhong W.D., Wen N., Jiang H., Zhu P., Chen Z.N. Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J. Biol. Chem. 2008, 283:18056-18065.
17. Nabeshima K., Iwasaki H., Koga K., Hojo H., Suzumiya J., Kikuchi M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol. Int. 2006, 56:359-367.
18. Sienel W., Polzer B., Elshawi K., Lindner M., Morresi-Hauf A., Vay C., Eder F., Passlick B., Klein C.A. Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Mod. Pathol. 2008, 21:1130-1138.
19. Reimers N., Zafrakas K., Assmann V., Egen C., Riethdorf L., Riethdorf S., Berger J., Ebel S., Janicke F., Sauter G., Pantel K. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin. Cancer Res. 2004, 10:3422-3428.
20. Li Y., Xu J., Chen L., Zhong W.D., Zhang Z., Mi L., Zhang Y., Liao C.G., Bian H.J., Jiang J.L., Yang X.M., Li X.Y., Fan C.M., Zhu P., Fu L., Chen Z.N. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology 2009, 54:677-687.
21. Rucci N., Millimaggi D., Mari M., Del F.A., Bologna M., Teti A., Angelucci A., Dolo V. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Cancer Res. 2010, 70:6150-6160.
22. Yang J.M., O'Neill P., Jin W., Foty R., Medina D.J., Xu Z., Lomas M., Arndt G.M., Tang Y., Nakada M., Yan L., Hait W.N. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim. J. Biol. Chem. 2006, 281:9719-9727.
23. Tang Y., Nakada M.T., Rafferty P., Laraio J., McCabe F.L., Millar H., Cunningham M., Snyder L.A., Bugelski P., Yan L. Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol. Cancer Res. 2006, 4:371-377.
24. Sun J., Hemler M.E. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001, 61:2276-2281.
25. Li Q.Q., Wang W.J., Xu J.D., Cao X.X., Chen Q., Yang J.M., Xu Z.D. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci. 2007, 98:1064-1069.
26. Slomiany M.G., Grass G.D., Robertson A.D., Yang X.Y., Maria B.L., Beeson C., Toole B.P. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res. 2009, 69:1293-1301.
27. Hao J., Madigan M.C., Khatri A., Power C.A., Hung T.T., Beretov J., Chang L., Xiao W., Cozzi P.J., Graham P.H., Kearsley J.H., Li Y. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS One 2012, 7:e40716.
28. Cui H.Y., Guo T., Wang S.J., Zhao P., Dong Z.S., Zhang Y., Jiang J.L., Chen Z.N., Yu X.L. Dimerization is essential for HAb18G/CD147 promoting tumor invasion via MAPK pathway. Biochem. Biophys. Res. Commun. 2012, 419:517-522.
29. Li M., Zhai Q., Bharadwaj U., Wang H., Li F., Fisher W.E., Chen C., Yao Q. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 2006, 106:2284-2294.
30. Xu J., Xu H.Y., Zhang Q., Song F., Jiang J.L., Yang X.M., Mi L., Wen N., Tian R., Wang L., Yao H., Feng Q., Zhang Y., Xing J.L., Zhu P., Chen Z.N. HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol. Cancer Res. 2007, 5:605-614.
31. Corsino P.E., Davis B.J., Norgaard P.H., Parker N.N., Law M., Dunn W., Law B.K. Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component. Neoplasia 2008, 10:1240-1252.
32. Han M., Liu M., Wang Y., Mo Z., Bi X., Liu Z., Fan Y., Chen X., Wu C. Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol. Cell Biochem. 2012, 363:427-436.
33. Pierceall W.E., Woodard A.S., Morrow J.S., Rimm D., Fearon E.R. Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines. Oncogene 1995, 11:1319-1326.
34. Hiraguri S., Godfrey T., Nakamura H., Graff J., Collins C., Shayesteh L., Doggett N., Johnson K., Wheelock M., Herman J., Baylin S., Pinkel D., Gray J. Mechanisms of inactivation of E-cadherin in breast cancer cell lines. Cancer Res. 1998, 58:1972-1977.
35. Hajra K.M., Ji X., Fearon E.R. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 1999, 18:7274-7279.
36. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
37. Feig C., Gopinathan A., Neesse A., Chan D.S., Cook N., Tuveson D.A. The pancreas cancer microenvironment. Clin. Cancer Res. 2012, 18:4266-4276.
38. Sappino A.P., Skalli O., Jackson B., Schurch W., Gabbiani G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int. J. Cancer 1988, 41:707-712.
39. Huang C., Sun Z., Sun Y., Chen X., Zhu X., Fan C., Liu B., Zhao Y., Zhang W. Association of increased ligand cyclophilin A and receptor CD147 with hypoxia, angiogenesis, metastasis and prognosis of tongue squamous cell carcinoma. Histopathology 2012, 60:793-803.
40. Pertega-Gomes N., Vizcaino J.R., Miranda-Goncalves V., Pinheiro C., Silva J., Pereira H., Monteiro P., Henrique R.M., Reis R.M., Lopes C., Baltazar F. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer, BMC. Cancer 2011, 11:312.
41. Nakamura K., Kodama J., Hongo A., Hiramatsu Y. Role of emmprin in endometrial cancer, BMC. Cancer 2012, 12:191.
42. Zhang Q., Zhou J., Ku X.M., Chen X.G., Zhang L., Xu J., Chen G.S., Li Q., Qian F., Tian R., Wen N., Chen Z.N. Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. Eur. J. Cancer Prev. 2007, 16:196-202.
43. Zhang Q., Chen X., Zhou J., Zhang L., Zhao Q., Chen G., Xu J., Qian F., Chen Z. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol. Ther. 2006, 5:808-814.
44. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
45. Moonsom S., Tayapiwatana C., Wongkham S., Kongtawelert P., Kasinrerk W. A Competitive ELISA for quantifying serum CD147: reduction of soluble CD147 levels in cancer patient sera. Hybridoma (Larchmt.) 2010, 29:45-52.
46. Guirguis R., Javadpour N., Sharareh S., Biswas C., el-Amin W., Mansur I., Kim J.S. A new method for evaluation of urinary autocrine motility factor and tumor cell collagenase stimulating factor as markers for urinary tract cancers. J. Occup. Med. 1990, 32:846-853.
47. Javadpour N., Guirguis R. Tumor collagenase-stimulating factor and tumor autocrine motility factor as tumor markers in bladder cancer-an update. Eur. Urol. 1992, 21(Suppl. 1):1-4.
48. Bhagirath D., Abrol N., Khan R., Sharma M., Seth A., Sharma A. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder. Clin. Chim. Acta 2012, 413:1641-1646.